A precise and convenient high-performance liquid chromatography (HPLC) method has been established to assay nilotinib in human plasma. Chromatographic separation of nilotinib was performed on a LiChrosphere®100 RP-18(e) column (250 mm x 4.0 mm, 5 μm) using a mixture of acetonitrile and 0.01 M phosphate buffer (pH 3.0) (42 : 58, v/v) under isocratic conditions at a flow rate of 1.0 ml/min with ultraviolet (UV) detection at 266 nm. The calibration curve showed linearity at concentrations between 250 ng/ml and 5000 ng/ml (r 2>0.999). The mean±S.D. absolute recovery of nilotinib from plasma was 99.2±3.3%. The coefficients of variation of both intra- and inter-day precision were below 9.1%. These results indicate that this new HPLC-based quantification may be useful for therapeutic drug monitoring of nilotinib to help manage treatment in patients with chronic myeloid leukemia in clinical practice. © 2011 Pharmaceutical Society of Japan.
CITATION STYLE
Yuki, M., Yamakawa, Y., Uchida, T., Nambu, T., Kawaguchi, T., Hamada, A., & Saito, H. (2011). High-performance liquid chromatographic assay for the determination of nilotinib in human plasma. Biological and Pharmaceutical Bulletin, 34(7), 1126–1128. https://doi.org/10.1248/bpb.34.1126
Mendeley helps you to discover research relevant for your work.